FibroBiologics Statistics
Total Valuation
FibroBiologics has a market cap or net worth of $6.95 million. The enterprise value is $4.28 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroBiologics has 4.54 million shares outstanding. The number of shares has increased by 35.85% in one year.
| Current Share Class | 4.54M |
| Shares Outstanding | 4.54M |
| Shares Change (YoY) | +35.85% |
| Shares Change (QoQ) | +39.72% |
| Owned by Insiders (%) | 7.04% |
| Owned by Institutions (%) | 8.22% |
| Float | 3.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.82 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.39.
| Current Ratio | 3.61 |
| Quick Ratio | 2.78 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -81.61 |
Financial Efficiency
Return on equity (ROE) is -419.44% and return on invested capital (ROIC) is -95.23%.
| Return on Equity (ROE) | -419.44% |
| Return on Assets (ROA) | -79.85% |
| Return on Invested Capital (ROIC) | -95.23% |
| Return on Capital Employed (ROCE) | -211.82% |
| Weighted Average Cost of Capital (WACC) | 9.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.98% in the last 52 weeks. The beta is 1.10, so FibroBiologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -92.98% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 7.93 |
| Relative Strength Index (RSI) | 25.36 |
| Average Volume (20 Days) | 914,276 |
Short Selling Information
The latest short interest is 209,586, so 4.61% of the outstanding shares have been sold short.
| Short Interest | 209,586 |
| Short Previous Month | 873,527 |
| Short % of Shares Out | 4.61% |
| Short % of Float | 5.32% |
| Short Ratio (days to cover) | 0.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.65M |
| Pretax Income | -18.65M |
| Net Income | -18.65M |
| EBITDA | -16.41M |
| EBIT | -16.65M |
| Earnings Per Share (EPS) | -$8.35 |
Full Income StatementBalance Sheet
The company has $4.89 million in cash and $2.41 million in debt, with a net cash position of $2.48 million or $0.55 per share.
| Cash & Cash Equivalents | 4.89M |
| Total Debt | 2.41M |
| Net Cash | 2.48M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 6.16M |
| Book Value Per Share | 1.85 |
| Working Capital | 4.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.39 million and capital expenditures -$262,000, giving a free cash flow of -$16.66 million.
| Operating Cash Flow | -16.39M |
| Capital Expenditures | -262,000 |
| Depreciation & Amortization | 244,000 |
| Net Borrowing | 975,000 |
| Free Cash Flow | -16.66M |
| FCF Per Share | -$3.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.85% |
| Shareholder Yield | -35.85% |
| Earnings Yield | -275.54% |
| FCF Yield | -246.13% |
Analyst Forecast
The average price target for FibroBiologics is $8.00, which is 422.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 422.88% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -51.71% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 30, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Mar 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
